Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;3(2):68-77.
doi: 10.33696/immunology.3.080.

Review of the COVID-19 Risk in Multiple Sclerosis

Farhan Chaudhry  1   2 , Cristina Jageka  2 , Phillip D Levy  1 , Mirela Cerghet  2   3 , Robert P Lisak  3   4
Affiliations

Review of the COVID-19 Risk in Multiple Sclerosis

Farhan Chaudhry et al. J Cell Immunol. 2021.

Abstract

The ongoing pandemic of the novel coronavirus of 2019 (COVID-19) has resulted in over 1 million deaths, primarily affecting older patients with chronic ailments. Multiple sclerosis (MS) patients have been deemed particularly vulnerable given their high rates of disability and increased susceptibility to infections. There have also been concerns regarding disease-modifying therapy (DMT) during the pandemic as many DMTs may increase the risk of infection due to some of their immunosuppressive properties. Furthermore, due to MS-related chronic inflammatory damage within the central nervous system, there have been concerns for worsening neurological injury by COVID-19. This has resulted in an alarmingly high level of anxiety and stress among the MS community leading to a lack of compliance with medications and routine check-ups, and even failure to obtain treatment for relapse. However, there is currently substantial evidence that MS and most DMT usage is not associated with increased COVID-19 severity. MS patients who suffer worse outcomes were more likely to be older and suffer from significant disabilities and comorbid conditions, which would also be expected from those in the general population. Likewise, there is little if any evidence demonstrating an increased susceptibility of MS patients to COVID-19-related neurological complications. Therefore, we aim to summarize the most recent findings related to COVID-19 and MS demonstrating that MS and most DMTs do not appear as risk factors for severe COVID-19.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Venn Diagram between Characteristics of Multiple Sclerosis and Risk Factors for COVID-19.
The Venn diagram shows known overlaps between characteristics of MS and known risk factors for COVID-19.
Figure 2:
Figure 2:. Risk-factors Associated with COVID-19 Risk in MS.
Figure shows risk-factors associated with worse COVID-19 outcomes in MS patients. *= Progressive forms of MS have yet to be found to be statistically significant.
See this image and copyright information in PMC

References

    1. Yadaw AS, Li Y-c, Bose S, Iyengar R, Bunyavanich S, Pandey G. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. The Lancet Digital Health. 2020;2(10):e516–e525. - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. - PMC - PubMed
    1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. - PMC - PubMed
    1. Shi SM, Bakaev I, Chen H, Travison TG, Berry SD. Risk Factors, Presentation, and Course of Coronavirus Disease 2019 in a Large, Academic Long-Term Care Facility. J Am Med Dir Assoc. 2020;21(10):1378–1383 e1371. - PMC - PubMed
    1. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. New England Journal of Medicine. 2020;382(26):2534–2543. - PMC - PubMed

LinkOut - more resources